Outpace Bio

Outpace Bio is a clinical-stage biotechnology company based in Seattle, Washington.

Founded in 2019, the company specializes in AI-powered protein design to develop next-generation T cell therapies, including CAR-T and TCR-T, aimed at treating solid tumors. Their mission is to enhance the efficacy and safety of these therapies, addressing the challenges faced in treating the 95% of cancers that are solid tumors. The company utilizes a modular platform that combines computational protein design, machine learning, synthetic biology, and immunology. This innovative approach allows Outpace Bio to create engineered T cell therapies with improved tumor access, functional persistence, and reduced toxicity. Their lead programs include OPB-101, a CAR-T therapy targeting mesothelin for ovarian cancer, and OPB-201, a TCR-T therapy for endometrial cancer. Outpace Bio also engages in strategic collaborations and technology licensing to integrate its solutions into other cell therapy products, further advancing the field of cancer treatment.